Nephrogenic systemic fibrosis is associated with hypophosphataemia: A case-control study

Rheumatology (United Kingdom)

Volumn 53, Issue 9, 2014, Pages 1613-1617

  Bernstein, Elana J ^a   Isakova, Tamara ^b   Sullivan, Mary E ^c   Chibnik, Lori B ^c   Wolf, Myles ^b   Kay, Jonathan ^d  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Chronic kidney disease; Dialysis; Fibroblast growth factor 23; Gadolinium; Magnetic resonance imaging; Nephrogenic systemic fibrosis; Phosphorus

Indexed keywords

CALCIUM; FIBROBLAST GROWTH FACTOR 23; GADODIAMIDE; GADOLINIUM PENTETATE MEGLUMINE; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CASE CONTROL STUDY; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; HUMAN; HYPOPHOSPHATEMIA; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; PARATHYROID HORMONE BLOOD LEVEL; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VITAMIN BLOOD LEVEL;

EID: 84906829806     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu151     Document Type: Article

References (13)

1. Girardi M, Kay J, Elston DM et al. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 2011;65:1095-106.
2. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007;22: 3174-8.
3. Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 2008;158: 273-80.
4. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol 2007;18:1637-47.
5. Imanishi Y, Inaba M, Nakatsuka K et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004;65:1943-6.
6. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005;16:2205-15.
7. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393-408.
8. Fretellier N, Idee JM, Guerret S et al. Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest Radiol 2011;46: 85-93.
9. Jongbloed F, Galassi A, Cozzolino M et al. Clinical significance of FGF-23 measurement in dialysis patients. Clin Nephrol 2011;76:201-9.
10. Owen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993;329: 1001-6.
11. Idee JM, Port M, Medina C et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology 2008; 248:77-88.
12. Sieber MA, Pietsch H, Walter J et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 2008;43:65-75.
13. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56:21-6.